All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Gennbio Co. Ltd. has signed an agreement with fellow Korean biotech Genexine Inc. to in-license two immunosuppressant drug candidates called GX-P1 (PD-L1 hyfc) and BSF-110 (PD-L1-hyFc-1L10m).
